These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 28953016

  • 1. Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab.
    Pouldar D, Elsensohn A, Ortenzio F, Shiu J, McLeod M, de Feraudy S.
    Am J Dermatopathol; 2018 Mar; 40(3):e36-e37. PubMed ID: 28953016
    [Abstract] [Full Text] [Related]

  • 2. Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease.
    Misago N, Narisawa Y.
    Am J Dermatopathol; 2012 May; 34(3):325-9. PubMed ID: 22172959
    [Abstract] [Full Text] [Related]

  • 3. Vasculitis in erythema induratum of Bazin: a histopathologic study of 101 biopsy specimens from 86 patients.
    Segura S, Pujol RM, Trindade F, Requena L.
    J Am Acad Dermatol; 2008 Nov; 59(5):839-51. PubMed ID: 19119100
    [Abstract] [Full Text] [Related]

  • 4. Crohn's disease with anorectal stenosis successfully treated with vedolizumab.
    Urlep D, Orel R.
    World J Pediatr; 2017 Aug; 13(4):394-395. PubMed ID: 28540693
    [No Abstract] [Full Text] [Related]

  • 5. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [Abstract] [Full Text] [Related]

  • 6. Sweet syndrome after treatment with vedolizumab in a patient with Crohn's disease.
    Martínez Andrés B, Sastre Lozano V, Sánchez Melgarejo JF.
    Rev Esp Enferm Dig; 2018 Aug; 110(8):530. PubMed ID: 29900741
    [Abstract] [Full Text] [Related]

  • 7. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab.
    Wichmann A, Krugliak Cleveland N, Rubin DT.
    Am J Gastroenterol; 2016 Apr; 111(4):577. PubMed ID: 27125715
    [No Abstract] [Full Text] [Related]

  • 8. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP, Domènech E.
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [Abstract] [Full Text] [Related]

  • 9. Vedolizumab for Crohn's disease.
    Mosli MH, Feagan BG.
    Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
    [Abstract] [Full Text] [Related]

  • 10. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M, Cross RK.
    Expert Opin Drug Saf; 2015 Mar; 14(9):1473-9. PubMed ID: 26138111
    [Abstract] [Full Text] [Related]

  • 11. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S, Dignass AU, Hartmann H, Kruis W, Rogler G, Siegmund B, Stallmach A, Witte C, Bokemeyer B.
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC, Bressler B.
    Immunotherapy; 2014 Jun; 6(9):963-71. PubMed ID: 25341118
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG.
    Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.
    Huff-Hardy K, Bedair M, Vazquez R, Burstein E.
    Inflamm Bowel Dis; 2017 Oct; 23(10):E49. PubMed ID: 28858074
    [No Abstract] [Full Text] [Related]

  • 18. Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease.
    Rath T, Bojarski C, Neurath MF, Atreya R.
    Gastrointest Endosc; 2017 Aug; 86(2):406-408. PubMed ID: 28137597
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
    Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.